On November 6th, GTHP will meet with the FDA to discuss the approval chances of their medical device. If GTHP receives approval, the stock could rise as high as $3 per share.
"Aeterna Zentaris Announces Data and Safety Monitoring Board Scheduled to Complete Second Interim Analysis of the ZoptEC Phase 3 Trial in Endometrial Cancer in Early October"
"SPPI has been the topic of several analyst reports. RBC Capital raised their price target on Spectrum Pharmaceuticals from $12 to $13 and gave the stock an “outperform” rating in a research report"
Source: Spectrum Pharmaceuticals Receives Average Rating of “Buy” from Analysts
Dakota Financial News
XenoPort, Inc. (Nasdaq:XNPT) announced today that it will provide access via the World Wide Web to its presentation at the Morgan Stanley Global Healthcare Conference. The live presentation will occur at 11:50 a.m. Pacific Time (2:50 p.m. Eastern Time) on Wednesday, September 16, 2015.